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Abstract
Background: Obese asthmatics tend to have poorly controlled asthma, and resistance to standard asthma
controller medications. The purpose of this study was to determine the efficacy of pioglitazone, an anti-diabetic
medication which can alter circulating adipokines and have direct effects on asthmatic inflammation, in the
treatment of asthma in obesity.
Methods: A two-center, 12-week, randomized, placebo-controlled, double-blinded trial. Treatments were randomly
assigned with concealment of allocation. The primary outcome was difference in change in airway reactivity
between participants assigned to pioglitazone versus placebo at 12 weeks.
Results: Twenty-three participants were randomized to treatment, 19 completed the study. Median airway reactivity,
measured by PC20 to methacholine was 1.99 (IQR 3.08) and 1.60 (5.91) mg/ml in placebo and pioglitazone group at
baseline, and 2.37 (15.22) and 5.08 (7.42) mg/ml after 12 weeks, p = 0.38. There was no difference in exhaled nitric
oxide, asthma control or lung function between treatment groups over the 12 week trial. Participants assigned to
pioglitazone gained a significant amount more weight than those assigned to placebo (pioglitazone group mean
weight 113.6, CI 94.5-132.7 kg at randomization and 115.9, CI 96.9-135.1 at 12 weeks; placebo mean weight 127.5,
CI 108.4 – 146.6 kg at randomization and 124.5, CI 105.4 – 143.6 kg at 12 weeks; p = 0.04).
Conclusions: This pilot study suggests limited efficacy for pioglitazone in the treatment of poorly controlled asthma
in obesity, and also the potential for harm, given the weight gain in those assigned to active treatment, and the
association between increased weight and worse outcomes in asthma.
Trial Registration: Clinicaltrials.gov (NCT00634036)
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Background
The majority of adults with poorly controlled asthma in
the United States are obese [1]. Obese asthmatics are
more likely to have moderate persistent or severe
asthma and suffer from more frequent exacerbations
[2]. One study suggested that obese asthmatics had a
nearly five-fold increased risk of hospitalization for
asthma compared with lean asthmatics [3]. One reason
for this poor asthma control, is that they do not respond
as well to standard asthma therapy [4, 5], and in vitro
studies suggest that they have intrinsic steroid resist-
ance [6]. There is an urgent need to find effective treat-
ments for obese asthmatics, these patients now
represent the majority of asthmatics, and are more
likely to have poorly controlled disease than lean indi-
viduals [1].
The pathogenesis of asthma in obesity is likely very differ-
ent from the pathogenesis of asthma in lean individuals
with typical early-onset allergic asthma. The mass of adi-
pose tissue in obesity may contribute to mechanical
changes in the respiratory system. In our earlier work we
have shown that obese asthmatics have evidence of in-
creased airway oxidative stress [7, 8], and decreased periph-
eral lung compliance [9]. The causes of this increased
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airway oxidative stress and decreased peripheral lung com-
pliance are not known, but could be related to mediators
produced by adipose tissue which may have direct effects
on the lung. In obese individuals adipose is an active meta-
bolic organ which produces multiple mediators such as lep-
tin which have widespread pro-inflammatory effects, and
also decreased levels of mediators with anti-inflammatory
effects such as adiponectin [10]. Indeed, we have shown
that obese asthmatics have increased leptin and decreased
adiponectin in visceral adipose tissue compared to obese
non-asthmatics, and that visceral fat leptin expression corre-
lates directly with airway reactivity in obese asthmatics [11].
Increased leptin and decreased adiponectin from adipose tis-
sue may contribute to the pathogenesis of asthma in obesity.
Certain medications alter the production of adipokines
by adipose tissue. The thiazolidinediones (TZDs) are a class
of drugs that activate the nuclear receptor peroxisome pro-
liferator activated receptor gamma (PPARγ), a transcription
factor for genes involved in lipid biosynthesis and glucose
metabolism. These medications are primarily used in the
treatment of diabetes. They are insulin sensitizing drugs
which act by increasing glucose uptake by adipose tissue
and muscle, and also by altering adipokine expression; be-
cause of their mechanism of action, they do not produce
hypoglycemia in non-diabetic subjects. Previous studies
have suggested that treatment with TZD’s are not only effi-
cacious in diabetes, but can be effective in the treatment of
metabolic complications of obesity such as steatohepatitis
[12]. TZD’s could be efficacious in the treatment of obese
asthma through metabolic effects on adipose tissue.
PPARγ agonists also have direct effects on the airway
in asthma. PPARγ is expressed in bronchial epithelium
and submucosa of human (non-obese) asthmatic sub-
jects [13]. Data from animal experiments suggest that
treatment with PPAR-γ agonists reduce the ability of anti-
gen presenting cells to activate T cells and induce eosino-
philic airway inflammation – inflammation characteristic
of TH2 high asthma [14]. PPARγ agonists reduce airway
hyperresponsiveness, measures of oxidative stress, colla-
gen deposition and mucus hypersecretion in an allergic
mouse models of asthm [15–17]. TZD medications could
be efficacious in the treatment of asthma through direct
effects on the airway.
We hypothesized that in obese poorly controlled asth-
matics, the addition of pioglitazone to standard asthma
therapy would reduce bronchial hyperresponsiveness
when compared to placebo. We also hypothesized that
pioglitazone would improve asthma control and lung
function compared with placebo.
Methods
Study Design
A randomized, placebo-controlled, parallel arm, double-
blinded study of pioglitazone for the treatment of poorly
controlled obese asthmatics. This study was conducted at
two centers (the Universities of Vermont and Pittsburgh)
from March 2010 – April 2013. After a four week run-in,
participants were randomized to pioglitazone starting at
30 mg/day and increased to 45 mg/day after two weeks,
or matching placebo (provided by Takeda). Allocation ra-
tio was 1:1. An independent 3rd party (Investigational
Drug Services at the University of Pittsburgh) prepared
and distributed blinded study drug kits to the study sites.
The University of Pittsburgh Investigational Drug Service
maintained the master randomization schema and com-
municated all study drug assignments to the clinical sites
when patients were enrolled. Block randomization was
performed to assure a balanced distribution of covariates
(age and gender). The blind was broken for the data ana-
lysis, after completion of all study procedures. This trial
was registered at clinicaltrials.gov (NCT00634036), an
Investigational New Drug Application was approved by
the FDA, and the study was approved by the institutional
review board at both institutions. Informed consent was
obtained from all study participants.
Eligibility Criteria
The goal of this study was to enroll obese adults with
moderate to severe asthma. Inclusion criteria included:
physician diagnosis of asthma, poorly-controlled asthma
defined as a Juniper asthma control questionnaire (ACQ)
score ≥ 1.5 [18], absence of active smoking (none in last
12 months and <10 pack-years total), BMI 30–60 kg/m2,
ages 18–60 years, PC20 to methacholine of < 16 mg/ml,
ability to understand and sign the consent form, on a
stable dose of inhaled corticosteroid for at least 4 weeks
prior to study entry, FEV1 ≥ 60 % predicted. Exclusion cri-
teria included the following: use of systemic steroids
within the past 4 weeks; lung disease other than asthma;
significant non-pulmonary co-morbidities; B-type natri-
uretic peptide (BNP) >400 pg/mL; pregnant or lactating;
currently taking a beta blocker, a CYP2C8 inhibitor or in-
ducer such as gemfibrozil or rifampin, a thiazolidinedione,
or allergic to TZD; use of nutritional supplements, antiox-
idants, or multivitamins; illicit drug use within the past
year; current or active upper respiratory infection; asthma
exacerbation within the past 4 weeks; institution of treat-
ment for sleep apnea planned; clinically significant abnor-
malities on 12-lead electrocardiogram.
Outcomes
The primary outcome measure was the change in airway
methacholine reactivity at 12 weeks compared with base-
line. Secondary outcomes included changes in Juniper
Asthma Control Score, spirometry and exhaled nitric
oxide, all measured at randomization, week 2, week 6 and
week 12.
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Prior to randomization, renal and liver function tests,
a complete blood count, brain natriuretic peptide (BNP)
and a fasting glucose were obtained, and these were
rechecked at 2, 6 and 12 weeks to monitor for any ad-
verse effects of Pioglitazone.
Statistical analysis
In order to test for significant treatment effects on out-
come measures of interest, mixed model repeated mea-
sures analyses of variance were conducted. In these
models, the outcome variables were treated continuously;
variables that were determined to be non-normally dis-
tributed (airway reactivity to methacholine, for example)
were log-transformed in order to satisfy the normality as-
sumption of the model. Fixed effects used in the models
were visit and treatment group, with random effect of sub-
ject. The group by visit interaction results of the analyses
were used to test for significant differences between
groups in changes in outcome measures over time,
using significance level alpha = 0.05. Analyses were
done using SAS, version 9.2, statistical analysis soft-
ware (SAS Institute, Inc., Cary, NC, USA).
Sample Size
The original sample size calculation was based upon es-
timates of clinically meaningful mean differences and
standard deviations derived from our studies of obese
asthmatics. The analysis was based upon a repeated
measures analysis of variance approach. The primary
outcome was airway reactivity to methacholine. We as-
sumed that after treatment with Pioglitazone, a 20 % fall
in FEV1 be detected using a mean methacholine dose of
6 mg/ml, an improvement over the baseline estimate of
3 mg/ml. It was assumed that those in the control group
would show no improvement over baseline. Using a
within-person standard deviation of 3.0, and the as-
sumptions indicated above, 17 individuals per group
would provide 80 % power with a 5 % significance level
to detect a difference between patients assigned to active
treatment versus placebo. Due to new safety concerns
which emerged about pioglitazone during the trial affect-
ing patient recruitment, a decision was made to halt the
study early after recruitment of only 23 subjects.
Results
The numbers of patients enrolled, randomized and com-
pleting the study are shown in Figure 1. The baseline
demographics of the participants are shown in Table 1.
The majority of study subjects were female and Cauca-
sian. They reported a high prevalence of comorbidities
such as atopy, GERD and depression. They had poor
asthma control confirmed with a high proportion experi-
encing a self-reported asthma exacerbation in the last
12 months, and oral corticosteroid use in the prior
12 months. Asthma was also poorly controlled as mea-
sured by the Juniper Asthma Control Score (with a score
of 1.5 or greater being indicative of poor asthma control).
Participants had a similar level of airway reactivity at
baseline. There was no significant difference in the
change in airway reactivity in participants assigned to pi-
oglitazone versus placebo during the treatment phase of
the trial (Table 2, Fig. 2).
There was no significant treatment effect on asthma
control as measured by the Juniper asthma control score
(Fig. 3a). Neither was there any effect on lung function
(Fig. 3b) or exhaled nitric oxide levels (Fig. 3c).
Leptin levels did not change significantly with treatment
(placebo 6.7 ± 0.75 at baseline to 6.55 ± 0.5 at week 12 and
pioglitazone 6.35 ± 0.6 to 6.55 ± 0.55 ng/ml, p = 0.46, re-
peated measures ANVOA). Adiponectin levels increased
slightly more in the pioglitazone group, though this did
Table 1 Baseline demographics of the study population
Placebo Pioglitazone
n 11 12
Female (%) 8 (72) 7 (52)
Age 41 ± 14.1 39.4 ± 10
Age asthma onset 21 ± 18.9 15 ± 11
Race
Caucasian 9 (82) 8 (66.6)
Black 2 (18) 4 (33.3)
BMI 43.5 ± 7.8 38.8 ± 6.8
Seasonal allergies (%) 10 (91) 10 (83)
GERD (%) 5 (45) 7 (58)
Depression (%) 6 (55) 7 (58)
Asthma exacerbation in last 12 months (%) 7 (64) 6 (50)
Oral steroids in last 12 months (%) 4 (36) 7 (58)
Inhaled corticosteroid n (%) 11 (100) 12 (100)
High dose* (n) 5 4
Medium dose (n) 4 8
Low dose (n) 2 0
Long acting beta agonist, n (%) 9 (81.8) 10 (83.3)
Short acting beta agonist,n (%) 11 (100) 11 (92)
FeNO (ppb) 30.8 ± 28.4 27.6 ± 27.8
IgE (IU/ml) 575 ± 544.7 291.2 ± 313.2
Juniper Asthma Control 2.48 ± 1.30 1.75 ± 0.63
FEV1 (% pred pre BD) 81.5 ± 15.2 82.3 ± 12.1
FVC (% pred. pre BD) 85.3 ± 16.2 86.8 ± 13.7
FEV1/FVC (% pred. pre BD) 94.9 ± 7.67 95.3 ± 11.12
FEV1 (% pred. post BD) 88.1 ± 4.6 77.3 ± 25.1
FVC (% pred. post BD) 88.3 ± 16.3 79.5 ± 27.6
FEV1/FVC (% pred. post BD) 97.8 ± 7.82 90.9 ± 31.2
*High, medium and low dose of ICS defined according to GINA guidelines [41]
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not reach statistical significance (placebo 409.4 ± 49.6 to
427.7 ± 47.3 ng/ml, pioglitazone 431.6 ± 40.8 to 479.8 ±
45.4 ng/ml. p = 0.24 for interaction between treatment
and time, repeated measures analysis of variance).
We monitored liver function tests, B-naturetic peptide
and complete blood counts in study subjects at each visit;
no laboratory abnormalities developed in any of the subjects
during study treatment. We asked participants about symp-
toms and infections at every study visit, and there was no
difference in these symptoms or infections between partici-
pants assigned to placebo or pioglitazone (Table 3). There
was a significant difference in change in weight between the
two groups; participants on pioglitazone gained 2.3 kg
(mean weight 113.6, CI 94.5-132.7 kg before randomization;
115.9, CI 96.9-135.1 at 12 weeks), whereas participants on
placebo lost 3.0 kg over the course of the trial (mean weight
127.5, CI 108.4 – 146.6 kg at randomization; 124.5, CI 105.4
– 143.6 kg at 12 weeks), p= 0.04.
Discussion
In this 12 week randomized, placebo-controlled pilot
study, we found no difference in pioglitazone versus pla-
cebo for the treatment of asthma. Of concern, we found
a significant difference in change in weight over the
course of the trial: participants on pioglitazone gained
significantly more weight than those assigned to placebo.
Although only a small pilot trial, these results suggest
that systemic pioglitazone is unlikely to be of benefit in
the treatment of obese patients with asthma. Although
this study suggests that systemic thiazolidinediones are
unlikely to be useful for the treatment of asthma because
of side-effects, it is possible that an inhaled formulation
targeting the airway may obviate some of these side
effects.
Animal models of asthma have implicated PPARγ re-
ceptors in the airway in the pathogenesis of asthma, and
suggested that pioglitazone might be efficacious in the
treatment of allergic asthma in lean allergic animal
models of asthma [19, 20] A recent single center cross-
over study showed that rosiglitazone (another TZD
medication, in the same class as pioglitazone) had mod-
est efficacy in reducing the late asthmatic response to al-
lergen challenge in mild-allergic asthmatics [21], and
Spears et al. found a significant improvement in lung
function in smoking asthmatics treated for 4 weeks with
rosiglitazone compared with inhaled corticosteroids [22].
Rosiglitazone has been associated with an increased risk
Table 2 Change in airway reactivity
placebo pioglitazone P-value*
PC20 at baseline (mg/ml) 1.99 (3.08) 1.60 (5.91)
n = 11 n = 12
PC20 at 12 weeks (mg/ml) 2.37 (15.22) 5.08 (7.42)
n = 9 n = 10 0.38
Values shown are median and IQR
*P-value shown for mixed model repeated measures analysis of variance,
treatment by time interaction
Participants assessed for eligibility and 
enrolled in study
(n=28) 
Randomized
(n=23)
Pioglitazone
n=12 
Placebo
n=11 
Week 6
n=11 Week 6
n=10
Week 12
n=9 
Week 12
n=10 
Fig. 1 Eligibility screening, randomization and follow up of study participants. All patients were included in the intention to treat analysis based
upon the assigned treatment
Dixon et al. Respiratory Research  (2015) 16:143 Page 4 of 8
of cardiovascular events [23], and so we chose to study
pioglitazone which appears to have a more acceptable
safety profile [24].
We stopped our study after recruitment of only 23
participants. During the study, new safety concerns
emerged about pioglitazone in the development of blad-
der cancer [25]. Our power calculations suggested we
needed 17 participants per group to detect a statistically
significant difference between groups. However, given
the new safety concerns, the lack of trend towards effi-
cacy, and possible harm related to weight gain, our re-
sults suggest that systemic TZD’s are unlikely to be of
benefit in obese asthmatics. Our study does not address
whether pioglitazone may be of benefit in lean asth-
matics, or if airway targeted therapy might be efficacious
in the treatment of obese asthmatics.
Previous studies have implicated adiponectin and lep-
tin in the pathogenesis of asthma in obese individuals.
Sood et al. found that high sputum adiponectin was as-
sociated with low risk of asthma (obesity is associated
with low adiponectin), even after adjustment for markers
of adiposity and circulating adiponectin [26]. Shore et al.
have shown that increased serum adiponectin attenuates
allergic airway responsiveness and inflammation in lean
mice [27 28], and Medoff et al. have shown that adipo-
nectin deficiency increases airway eosinophilia [29]. The
exact mechanism by which adiponectin may protect
against asthma is not known, though adiponectin recep-
tors are expressed by many cells in the lung, and adipo-
nectin may have effects on innate and adaptive immune
function [30], smooth muscle [31], bronchial epithelial
cells [11] and endothelial function [32]. Leptin, which in-
creases in proportion to obesity, has been associated
with asthma in obesity. Visceral fat leptin levels correlate
with airway reactivity in obese asthmatics [11], and
Shore et al. have found that leptin infusion increases air-
way reactivity in lean allergen challenged mice [33]. Lep-
tin may have pleotropic effects in the airway: it is
involved in neonatal lung development, effects innate
and adaptive immunity [34], and parasympathetic signal-
ing in the airway [35]. High leptin and low adiponectin
are thought to contribute to asthma in obesity through a
number of different pathways.
We do not know why treatment with pioglitazone did
not lead to an improvement in asthma in our partici-
pants: it is possible that the increase in adiponectin pro-
duced by our intervention was not sufficient to have a
clinically significant impact on asthma outcomes in this
patient population. The dose of pioglitazone used in this
study has been reported to increase circulating adipo-
nectin levels, and this strongly correlates with improve-
ment in non-alcoholic fatty liver [12]. In fact
pioglitazone, at the doses used in the current trial,
has significant efficacy in the treatment of nonalco-
holic fatty liver disease, when compared with placebo
[12, 36]. However, we did not see a significant in-
crease in adiponectin levels (though there was a nu-
meric increase), and this may be related to the
shorter duration of our study than have been used for
the treatment of nonalcoholic fatty liver disease. We
did not detect any change in leptin levels with pioglit-
azone treatment: pioglitazone can decrease circulating
leptin levels, though this is more variable [37]. It is
also possible that this short-term study was not of
sufficient duration to significantly alter the pathways
that contribute to asthma in obese adults. This may
be true if long term obesity significantly affects the
mechanical properties of the lung: we have shown
that obese asthma is particularly associated with de-
creased compliance of the lung periphery, and this
does not improve with weight loss to the same degree
that mechanical changes improve in obese controls with-
out asthma going through bariatric surgery [9]. There are
also multiple co-morbidities that we have shown are likely
to contribute to asthma control in obesity, such as ob-
structive sleep apnea and depression [38, 39]; treatment
with TZD medication is unlikely to affect these other
comorbidities.
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Fig 2 Change in airway reactivity in participants assigned to placebo versus pioglitazone (p = 0.38)
Dixon et al. Respiratory Research  (2015) 16:143 Page 5 of 8
We are not aware of any prior studies of TZD’s for the
treatment of asthma in obesity. Shore et al. have studied
the efficacy of the biguanide metform, an anti-diabetic
medication which increases insulin sensitivity through
effects on AMP-activated protein kinase: metformin has
no effect on airway reactivity or inflammation in re-
sponse to ozone [40]. Metformin significantly reduced
hyperglycemia, but did not affect adiponectin or leptin
levels in obese mice, and so this study did not address
whether an anti-diabetic medication that could alter
these adipokine levels might have efficacy in the treat-
ment of obese asthma.
Weight gain is a recognized side effect of treatment
with medications such as pioglitazone. In a 6 month
study of pioglitazone (using the identical dose we used
in the current trial) and a hypocaloric diet compared
with placebo and hypocaloric diet, Belfort et al. found
that participants assigned to pioglitazone gained an aver-
age of 2.5 kg, and increased body fat by 1.5 %, whereas
those on placebo lost a non-significant amount of weight
[12]. Participants in this study gained a similar amount
of weight over a shorter time period, likely because they
were not being treated with a hypocaloric diet. Partici-
pants assigned to placebo in our study actually lost
weight, we do not know the reason for this, but specu-
late it may be related to the fact that we discussed the
possibility of weight gain during the informed consent
period, and all participants were provided with scales to
monitor their weight at home during the course of the
trial. This may have led to increased awareness of
weight, and weight loss in the placebo group.
Conclusions
In conclusion, although a number of studies suggest
there may be a link between adipokines and asthma, the
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Fig 3 Change in asthma outcomes for participants assigned to placebo
and pioglitazone. a Juniper asthma control score (p= 0.52) (b) Lung
function (FEV1 and FVC, % predicted) (p= 0.36 FEV1 and p= 0.15, FVC),
and (c) exhaled nitric oxide (ppb) (p= 0.99). P-values are for treatment by
time interactions (showing differences between treatment groups), using
mixed model repeated measures analysis of variance
Table 3 new self-reported symptoms and infections during
treatment phase of study
placebo Pio P-value*
Fatigue 0 0 -
headache 44 56 0.5
dizziness 11 22 0.5
URI 33 0 0.21
sore throat 22 44 0.62
abdominal pain 44 22 0.62
nausea 11 11 1
diarrhea 33 22 0.5
Skin rash 11 11 1
muscle aches 33 22 0.5
Fluid retention 0 0 -
Values shown are % of patients reporting symptoms
*p value for Fisher’s Exact Test
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current small study did not show any obvious efficacy
for pioglitazone in the treatment of poorly controlled
asthma. Of concern, there was a significant weight gain
in participants assigned to pioglitazone, which may sig-
nificantly impact on poor asthma control. These data
suggest that there is no role for systemic pioglitazone in
the treatment of asthma in obesity; future investigations
which uncover the link between obesity and asthma are
warranted to direct future intervention trials in this diffi-
cult patient population.
Competing interests
The authors report no conflicts of interest related to this research.
Dr Dixon has served on DSMB’s for Boehringer Ingelheim and Roche.
Authors’ contributions
AED: conceived study, participated in all phases of patient recruitment,
data analysis, drafting and revising manuscript. MS: participated in patient
recruitment, procedures, draft and revision of manuscript. MD: performed
data analysis, and revision of manuscript. LL: participated in patient
recruitment, procedures, draft and revision of manuscript. FH: conceived
study with AED, participated in all phases of patient recruitment, data
analysis, and revising manuscript. All authors read and approved the final
manuscript.
Acknowledgements
Funding:
American Lung Association: CG-82885-N.
National Institutes of Health: P30 GM103532.
Drug and Matching Placebo were kindly provided by Takeda: Takeda had
no role in designing, conducting, or approving the study or analyzing the
results.
Author details
1University of Vermont, Burlington, VT, USA. 2University of Pittsburgh,
Pittsburgh, PA, USA. 3Division of Pulmonary and Critical Care Medicine, Given
D209, 149 Beaumont Avenue, Burlington, VT 05405, USA.
Received: 23 May 2015 Accepted: 19 November 2015
References
1. Schatz M, Hsu JW, Zeiger RS, Chen W, Dorenbaum A, Chipps BE, et al.
Phenotypes determined by cluster analysis in severe or difficult-to-treat
asthma. J Allergy Clin Immunol. 2014;133:1549–56.
2. Dixon A. The treatment of asthma in obesity. Expert Rev Respir Med.
2012;6:331–40.
3. Vortmann M, Eisner MD. BMI and health status among adults with asthma.
Obesity (Silver Spring). 2008;16:146–52.
4. Boulet LP, Franssen E. Influence of obesity on response to fluticasone with
or without salmeterol in moderate asthma. Respir Med. 2007;101:2240–7.
5. Peters-Golden M, Swern A, Bird SS, Hustad CM, Grant E, Edelman JM.
Influence of body mass index on the response to asthma controller agents.
Eur Respir J. 2006;27:495–503.
6. Sutherland ER, Goleva E, Strand M, Beuther DA, Leung DY. Body mass and
glucocorticoid response in asthma. Am J Respir Crit Care Med. 2008;178:682–7.
7. Holguin F, Comhair SA, Hazen SL, Powers RW, Khatri SS, Bleecker ER, et al.
An association between L-arginine/asymmetric dimethyl arginine balance,
obesity, and the age of asthma onset phenotype. Am J Respir Crit Care
Med. 2013;187:153–9.
8. Holguin F, Fitzpatrick A. Obesity, asthma, and oxidative stress. J Appl Physiol
(1985). 2010;108:754–9.
9. Al-Alwan A, Bates JH, Chapman DG, Kaminsky DA, DeSarno MJ, Irvin CG, et
al. The nonallergic asthma of obesity. A matter of distal lung compliance.
Am J Respir Crit Care Med. 2014;189:1494–502.
10. Sood A, Shore SA. Adiponectin, leptin, and resistin in asthma: basic
mechanisms through population studies. J Allergy (Cairo). 2013;2013:785835.
11. Sideleva O, Suratt BT, Black KE, Tharp WG, Pratley RE, Forgione P, et al.
Obesity and asthma: an inflammatory disease of adipose tissue not the
airway. Am J Respir Crit Care Med. 2012;186:598–605.
12. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A
placebo-controlled trial of pioglitazone in subjects with nonalcoholic
steatohepatitis. N Engl J Med. 2006;355:2297–307.
13. Benayoun L, Letuve S, Druilhe A, Boczkowski J, Dombret MC, Mechighel
P, et al. Regulation of peroxisome proliferator-activated receptor
gamma expression in human asthmatic airways: relationship with
proliferation, apoptosis, and airway remodeling. Am J Respir Crit Care
Med. 2001;164:1487–94.
14. Hammad H, de Heer HJ, Soullie T, Angeli V, Trottein F, Hoogsteden HC, et
al. Activation of peroxisome proliferator-activated receptor-gamma in
dendritic cells inhibits the development of eosinophilic airway inflammation
in a mouse model of asthma. Am J Pathol. 2004;164:263–71.
15. Lee KS, Kim SR, Park SJ, Park HS, Min KH, Jin SM, et al. Peroxisome
proliferator activated receptor-gamma modulates reactive oxygen species
generation and activation of nuclear factor-kappaB and hypoxia-inducible
factor 1alpha in allergic airway disease of mice. J Allergy Clin Immunol.
2006;118:120–7.
16. Honda K, Marquillies P, Capron M, Dombrowicz D. Peroxisome proliferator-
activated receptor gamma is expressed in airways and inhibits features of
airway remodeling in a mouse asthma model. J Allergy Clin Immunol.
2004;113:882–8.
17. Woerly G, Honda K, Loyens M, Papin JP, Auwerx J, Staels B, et al.
Peroxisome proliferator-activated receptors alpha and gamma down-
regulate allergic inflammation and eosinophil activation. J Exp Med.
2003;198:411–21.
18. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and
validation of a questionnaire to measure asthma control. Eur Respir J.
1999;14:902–7.
19. Narala VR, Ranga R, Smith MR, Berlin AA, Standiford TJ, Lukacs NW, et al.
Pioglitazone is as effective as dexamethasone in a cockroach allergen-
induced murine model of asthma. Respir Res. 2007;8:90.
20. Belvisi MG, Mitchell JA. Targeting PPAR receptors in the airway for the
treatment of inflammatory lung disease. Br J Pharmacol. 2009;158:994–1003.
21. Richards DB, Bareille P, Lindo EL, Quinn D, Farrow SN. Treatment with a
peroxisomal proliferator activated receptor gamma agonist has a modest
effect in the allergen challenge model in asthma: a randomised controlled
trial. Respir Med. 2010;104:668–74.
22. Spears M, Donnelly I, Jolly L, Brannigan M, Ito K, McSharry C, et al.
Bronchodilatory effect of the PPAR-gamma agonist rosiglitazone in smokers
with asthma. Clin Pharmacol Ther. 2009;86:49–53.
23. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction
and death from cardiovascular causes. N Engl J Med. 2007;356:2457–71.
24. Betteridge DJ. CHICAGO, PERISCOPE and PROactive: CV risk modification in
diabetes with pioglitazone. Fundam Clin Pharmacol. 2009;23:675–9.
25. Ferwana M, Firwana B, Hasan R, Al-Mallah MH, Kim S, Montori VM, et al.
Pioglitazone and risk of bladder cancer: a meta-analysis of controlled
studies. Diabet Med. 2013;30:1026–32.
26. Sood A, Seagrave J, Herbert G, Harkins M, Alam Y, Chiavaroli A, et al.
High sputum total adiponectin is associated with low odds for asthma.
J Asthma. 2014;51:459–66.
27. Shore SA, Terry RD, Flynt L, Xu A, Hug C. Adiponectin attenuates allergen-
induced airway inflammation and hyperresponsiveness in mice. J Allergy
Clin Immunol. 2006;118:389–95.
28. Williams AS, Kasahara DI, Verbout NG, Fedulov AV, Zhu M, Si H, et al. Role of
the adiponectin binding protein, T-cadherin (Cdh13), in allergic airways
responses in mice. PLoS One. 2012;7, e41088.
29. Medoff BD, Okamoto Y, Leyton P, Weng M, Sandall BP, Raher MJ, et al.
Adiponectin deficiency increases allergic airway inflammation and
pulmonary vascular remodeling. Am J Respir Cell Mol Biol. 2009;41:397–406.
30. Cheng X, Folco EJ, Shimizu K, Libby P. Adiponectin induces pro-
inflammatory programs in human macrophages and CD4+ T cells. J Biol
Chem. 2012;287:36896–904.
31. Shin JH, Kim JH, Lee WY, Shim JY. The expression of adiponectin receptors
and the effects of adiponectin and leptin on airway smooth muscle cells.
Yonsei Med J. 2008;49:804–10.
32. Konter JM, Parker JL, Baez E, Li SZ, Ranscht B, Denzel M, et al. Adiponectin
attenuates lipopolysaccharide-induced acute lung injury through
suppression of endothelial cell activation. J Immunol. 2012;188:854–63.
Dixon et al. Respiratory Research  (2015) 16:143 Page 7 of 8
33. Shore SA, Schwartzman IN, Mellema MS, Flynt L, Imrich A, Johnston RA.
Effect of leptin on allergic airway responses in mice. J Allergy Clin Immunol.
2005;115:103–9.
34. Malli F, Papaioannou AI, Gourgoulianis KI, Daniil Z. The role of leptin in the
respiratory system: an overview. Respir Res. 2010;11:152.
35. Arteaga-Solis E, Zee T, Emala CW, Vinson C, Wess J, Karsenty G. Inhibition of
leptin regulation of parasympathetic signaling as a cause of extreme body
weight-associated asthma. Cell Metab. 2013;17:35–48.
36. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM,
et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
N Engl J Med. 2010;362:1675–85.
37. Esteghamati A, Noshad S, Rabizadeh S, Ghavami M, Zandieh A, Nakhjavani
M. Comparative effects of metformin and pioglitazone on omentin and
leptin concentrations in patients with newly diagnosed diabetes: a
randomized clinical trial. Regul Pept. 2013;182:1–6.
38. Kapadia SG, Wei C, Bartlett SJ, Lang J, Wise RA, Dixon AE, et al. Obesity and
symptoms of depression contribute independently to the poor asthma
control of obesity. Respir Med. 2014;108:1100–7.
39. Dixon AE, Clerisme-Beaty EM, Sugar EA, Cohen RI, Lang JE, Brown ED, et al.
Effects of obstructive sleep apnea and gastroesophageal reflux disease on
asthma control in obesity. J Asthma. 2011;48:707–13.
40. Shore SA, Williams ES, Zhu M. No effect of metformin on the innate airway
hyperresponsiveness and increased responses to ozone observed in obese
mice. J Appl Physiol (1985). 2008;105:1127–33.
41. Asthma GI. Global Strategy fo Asthma Management and Prevention. 2015.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Dixon et al. Respiratory Research  (2015) 16:143 Page 8 of 8
